Edition:
United Kingdom

Auris Medical Holding AG (EARS.OQ)

EARS.OQ on NASDAQ Stock Exchange Capital Market

1.30USD
23 May 2018
Change (% chg)

$-0.12 (-8.45%)
Prev Close
$1.42
Open
$1.41
Day's High
$1.44
Day's Low
$1.27
Volume
146,959
Avg. Vol
67,162
52-wk High
$9.70
52-wk Low
$1.24

Select another date:

Mon, May 7 2018

BRIEF-Auris Medical Receives Positive Scientific Advice From EMA On Development Plan And Regulatory Pathway For AM-111

* AURIS MEDICAL RECEIVES POSITIVE SCIENTIFIC ADVICE FROM EMA ON DEVELOPMENT PLAN AND REGULATORY PATHWAY FOR AM-111

BRIEF-Auris Medical Announces Early Repayment Of Part Of Its Loan Facility

* AURIS MEDICAL ANNOUNCES EARLY REPAYMENT OF PART OF ITS LOAN FACILITY

BRIEF-Thomas Meyer Reports 12.6 Pct Stake In Auris Medical As Of March 29

* THOMAS MEYER REPORTS 12.6 PCT STAKE IN AURIS MEDICAL HOLDING AG AS OF MARCH 29, 2018 - SEC FILING‍​ Source text: (https://bit.ly/2uJaqwA) Further company coverage:

BRIEF-Auris Regains Compliance With Nasdaq's Minimum Bid Price Requirement

* AURIS REGAINS COMPLIANCE WITH NASDAQ'S MINIMUM BID PRICE REQUIREMENT Source text for Eikon: Further company coverage:

BRIEF-Auris Medical Q4 Loss Per Share CHF 0.10

* AURIS MEDICAL PROVIDES BUSINESS UPDATE AND REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-Auris Medical Holding AG - Shareholders Approved Merger Between Co And Auris Medical Newco - SEC Filing

* AURIS MEDICAL HOLDING AG - ON MARCH 12, AT THE GENERAL MEETING, SHAREHOLDERS APPROVED MERGER BETWEEN CO AND AURIS MEDICAL NEWCO - SEC FILING

BRIEF-Auris Medical Provides Business Update

* AURIS MEDICAL HOLDING AG - PRELIMINARY TOP-LINE DATA FROM TACTT3 TRIAL INDICATE THAT STUDY DID NOT MEET ITS PRIMARY EFFICACY ENDPOINT

BRIEF-Auris Medical Holding AG Files For Resale Of Up To 7.5 Mln Common Shares Issuable Upon Exercise Of Certain Outstanding Warrants

* AURIS MEDICAL HOLDING AG FILES FOR RESALE OF UP TO 7.5 MILLION COMMON SHARES ISSUABLE UPON EXERCISE OF CERTAIN OUTSTANDING WARRANTS - SEC FILING Source text: [http://bit.ly/2BPfTod] Further company coverage:

BRIEF-Auris Medical Reports New Data Highlighting Superior Bioavailability Of AM-125

* AURIS MEDICAL REPORTS NEW DATA HIGHLIGHTING SUPERIOR BIOAVAILABILITY OF AM-125 COMPARED TO ORAL BETAHISTINE

BRIEF-Auris Medical Announces Pricing Of $5.5 Mln Registered Direct Offering

* AURIS MEDICAL ANNOUNCES PRICING OF $5.5 MILLION REGISTERED DIRECT OFFERING

Select another date: